Hormone receptors are the targets of endocrine drug therapies for breast cancer [17, 18], and endocrine drugs alone or combined with other medications could significantly benefit hormone-dependent breast cancer patients with ER/PR-positive tumors [19, 20]. Here, NR4A1 is linked to breast carcinoma.